Recruiting Your Own Patients
Part of Principal Investigator (PI) Training: Recruitment, Enrollment and Retention.
About 4 minutes. Free, in your language, no account needed.
Why this matters
The consent discussion has a whole module in this course and a whole module in the GCP course. The decision that happens before it has neither, and for a physician it is the harder one: whether to raise the trial with this patient at all.
That decision is made by you, usually in a clinic, usually with a patient who trusts you, and almost always without anyone else in the room. It is the least supervised act in the entire trial.
The asymmetry you are working inside
A patient hearing about a study from their own doctor is not hearing a neutral offer. Four things are true at once, and all four favor saying yes:
- You know things they do not, and they know you know them.
- Their future care depends on the relationship, or they believe it does.
- Declining feels like refusing help, or like ingratitude.
- If they are seriously ill, the trial may be the only forward-looking thing anyone has offered.
None of this makes recruitment wrong. Most trial participants are recruited by their own clinicians and that is appropriate. It means the pressure is structural, so it has to be managed structurally rather than by good intentions.
Three habits that manage it
Separate the offer from the treatment decision. Where the protocol allows, raise the study at a different visit from the one where you set their treatment plan. A person absorbing a diagnosis cannot weigh a research decision the same hour, and they will agree to almost anything.
Offer it to everyone eligible, not to the ones likely to say yes. Selective offering is the quiet failure here. If you find yourself skipping the difficult patient, the one who asks a lot of questions, or the one whose English is limited, your trial population has stopped representing the people who will take the drug — and the people you skipped were denied access. Both the science and the mission lose.
Have someone else do the consent discussion where you can. You raise it; a trained coordinator discusses it. You still meet them, and you still attest. The gap between the two conversations is where a patient finds room to say no.
Where recruitment pressure actually comes from
Be honest about the sources, because naming them defuses most of them.
| Pressure | What it does | The counter |
|---|---|---|
| An enrollment target you agreed at feasibility | Turns a clinical judgment into a quota | Your §2.2.1 estimate was evidence; if it was wrong, say so early |
| A per-participant payment or bonus | Rewards volume regardless of fit | Notice it at the eligibility decision; consider disclosing it |
| A sponsor asking for "one more before the cut-off" | Compresses the decision | The cut-off is theirs; the participant is yours |
| Competitive enrollment tables between sites | Makes recruitment a scoreboard | A slow honest site beats a fast site that gets closed |
| Your own belief the drug works | Removes equipoise | If you have lost equipoise, stop offering the trial |
Advertising and materials
Anything a potential participant sees is participant-facing material and needs written IRB or IEC approval before use (§2.4), including social media posts, posters, letters, and the script your coordinator uses on the telephone. Two rules follow:
- Nothing goes out unapproved, including a version you improved slightly.
- Nothing promises benefit. "You may benefit" is a claim about an unknown. Materials describe what the study is and what taking part involves.
And under §1.2.8 the committee reviews the amount and method of participant payment for coercion or undue influence. Reimbursement for time, travel and inconvenience is normal and right. A sum large enough to make someone accept a risk they otherwise would not is not.
The patients you should not approach
Some people are eligible on paper and should not be asked, or should be asked with extra protection:
- Your own employees, students or trainees — the power gradient is steeper than the clinical one.
- Anyone whose capacity to decide freely may be affected by expectation of benefit or fear of retaliation, which is the Glossary's own framing of vulnerability.
- Someone in acute distress, where the answer is to wait rather than to skip them permanently.
Waiting is almost always available. Skipping is a decision you should be able to defend.
Key takeaways
- The recruitment decision is the least supervised act in the trial, and the pressure on the patient is structural rather than personal.
- Separate the offer from the treatment decision; offer to everyone eligible; let someone else run the discussion where you can.
- Name the pressure sources — targets, payments, cut-offs, scoreboards, lost equipoise — and counter each deliberately.
- All participant-facing material needs prior IRB/IEC approval and may promise no benefit; §1.2.8 puts both the amount and the method of payment under review.